Redhill Biopharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.10.24	RedHill: BARDA Selects Opaganib For Development & Funding As Medical Countermeasure To Treat Ebola (RTTNews)
09.07.24	RedHill Biopharma To Stop Commercialization Of Aemcolo - Quick Facts (RTTNews)
11.03.24	RedHill Biopharma Receives New Patent For H. Pylori Treatment Talicia (RTTNews)
20.12.23	RedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus Study (RTTNews)
27.11.23	RedHill's Talicia Granted 5-year Market Exclusivity By FDA (RTTNews)
03.01.23	RedHill Biopharma Reports Positive Data From Phase 2 Study Of RHB-107 In Symptomatic COVID-19 (RTTNews)
14.11.22	RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published (PR Newswire)
19.10.22	RedHill's Oral Antiviral, Opaganib, Granted New COVID-19 Treatment Patent (RTTNews)
03.10.22	RedHill Says Its Oral Antivirals, Opaganib And RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5 (RTTNews)
17.08.22	RedHill Biopharma: RHB-204 Gets EU Orphan Drug Designation For NTM Infections (RTTNews)
23.06.22	DGAP-News: RedHill Biopharma veröffentlicht Highlights aus Q1/2022: Im Plan zu einem positiven operativen Cashflow in H2/22 (EQS Group)
11.04.22	DGAP-News: RedHill gibt effektive Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidaten Opaganib in vitro bekannt (EQS Group)
11.04.22	DGAP-News: RedHill gibt effektive in vitro-Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidat Opaganib in vivo bekannt (EQS Group)
15.03.22	DGAP-News: RedHill und Kukbo unterzeichnen Lizenzvereinbarung für oral verabreichtes Opaganib zur Behandlung von COVID-19 in Südkorea (EQS Group)
01.03.22	DGAP-News: RedHill gibt positive Phase-2-Studienergebnisse mit oral verabreichtem RHB-107 an nicht hospitalisierten COVID-19-Patienten bekannt (EQS Group)
17.02.22	DGAP-News: RedHill Biopharma meldet Rekord-Quartalsumsatz und erreicht zum ersten Mal kommerzielle Gewinnzone (EQS Group)
06.12.21	RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations (PR Newswire)
30.11.21	RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results (PR Newswire)
19.11.21	Pre-market Movers: TUSK, AQB, LGVN, CNTB, UWMC… (RTTNews)
15.11.21	RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients (PR Newswire)
08.11.21	RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill (PR Newswire)
06.10.21	Pre-market Movers: ACER, CEI, GTE, MARPS, PLTR… (RTTNews)
04.10.21	RedHill Says Phase 2/3 Data Shows 62% Reduction In Mortality With Oral Opaganib In COVID-19 Patients (RTTNews)
04.10.21	RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients (PR Newswire)
23.09.21	RedHill Biopharma Says Resolves Movantik Patent Litigation With Aurobindo (RTTNews)
23.09.21	RedHill Biopharma Announces Movantik Patent Litigation Settlement With Aurobindo (RTTNews)
14.09.21	RedHill Biopharma: Opaganib Fails To Meet Primary Endpoint In Phase 2/3 Study (RTTNews)
13.09.21	RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval (PR Newswire)
07.09.21	RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis (PR Newswire)
07.09.21	RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 (PR Newswire)
26.08.21	RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights (PR Newswire)
26.08.21	RedHill Biopharma: Opaganib Shows Strong Inhibition Of COVID-19 Delta Variant (RTTNews)
26.08.21	RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant (PR Newswire)
19.08.21	RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021 (PR Newswire)
22.07.21	RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex (PR Newswire)
21.07.21	RedHill Biopharma annonce qu'elle a traité le dernier patient d'une étude de phase 2/3 examinant l'administration orale de l'opaganib dans le traitement de la COVID-19 (PR Newswire)
20.07.21	RedHill Biopharma gibt bekannt, dass der letzte Patient die Phase 2/3-COVID-19-Studie mit oral verabreichtem Opaganib beendet hat (PR Newswire)
20.07.21	RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx (PR Newswire)
19.07.21	RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib (PR Newswire)
19.07.21	RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib (PR Newswire)
19.07.21	RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib (PR Newswire)
19.07.21	RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib (PR Newswire)
13.07.21	RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans (PR Newswire)
30.06.21	L'opaganib de RedHill Biopharma inhibe les variants de la COVID-19 dans une étude préclinique (PR Newswire)
29.06.21	RedHill Biopharmas Wirkstoffkandidat Opaganib zeigt hemmende Wirkung gegen COVID-19-Varianten in präklinischer Studie (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Redhill Biopharma Ltd (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten